Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Read More
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with diluted EPS up 15% year-on-year. ~65% of revenues were driven by semaglutide, or Wegovy (obesity)/Ozempic (diabetes). This is truly a miraculous drug, and as compounded versions of semaglutide cease to be manufactured, performance will improve in 2H25.
Read More
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat
Published: May 07, 2025 by: Schwab Network
Sentiment: Negative
Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI) "missed across the board" in its earnings and trimmed guidance.
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Novo Nordisk investors relieved after expected guidance cut
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the share price, which rose 4%.
Read More
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
Published: May 07, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due what Novo says is illegal compounding of GLP-1 medicines.
Read More
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a forward P/E ratio of 16.35x, make it an undervalued investment opportunity. Market concerns over minor market share losses are overblown; NVO remains the leader in a rapidly growing obesity and diabetes market.
Read More
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral
U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.
Read More
Novo Nordisk CEO says 'compounders took a part of our business away'
Published: May 07, 2025 by: CNBC International TV
Sentiment: Neutral
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Read More
Drugmaker Novo Nordisk drops gender representation requirements in the US
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.
Read More
Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.
Published: May 07, 2025 by: Market Watch
Sentiment: Neutral
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.
Read More
Novo Nordisk shares rise despite cut to 2025 outlook
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Investors breathed a sigh of relief on Wednesday as shares in Novo Nordisk (NYSE:NVO) rose 3% in early trading, despite the drugmaker trimming its sales and profit forecasts for 2025. The downgrade, which had largely been anticipated, brings an end to a four-year streak of upgrades driven by booming demand for its obesity drug Wegovy.
Read More
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
Published: May 07, 2025 by: WSJ
Sentiment: Negative
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.
Read More
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
Published: May 07, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Read More
Obesity drugmaker Novo Nordisk cuts 2025 outlook, posts Q1 profit above forecast
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its operating profit and sales outlook for the year.
Read More
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025
Read More
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Published: May 06, 2025 by: CNBC Television
Sentiment: Neutral
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Read More
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Published: May 06, 2025 by: Barrons
Sentiment: Negative
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.
Read More
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity (ECO), 11–14 May 2025. The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH). Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of …
Read More
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
Published: May 05, 2025 by: Schwab Network
Sentiment: Neutral
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy
Published: May 02, 2025 by: WSJ
Sentiment: Positive
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
Read More
U.S. FDA accepts Novo Nordisk's application for oral Wegovy
Published: May 02, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.
Read More
Why Is Novo Nordisk Stock Trading Higher On Friday?
Published: May 02, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis).
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Published: May 01, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
Read More
Why Novo Nordisk Stock Popped Today
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m.
Read More
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406